They work through different mechanisms, they release growth hormone in different patterns, they have different dosing schedules, and they suit different patients
Hyman M
Designing the release curve to start low and gradually increase (mimicking the dose escalation patients usually experience with weekly GLP-1s) is crucial to avoid overwhelming patients with side effects on the first dose
A quick, honest caveat Every sign above is also seen in far more common conditions: iron-deficiency anaemia, hypothyroidism, poor sleep, vitamin D or B12 deficiency, and depression, among others
Of note, glycemic control improved with HbA1c reductions reaching 0.8% with survodutide therapy, indicating preserved glycemic benefits despite GCG agonism, likely reflecting the predominant GLP-1 receptor activity ratio